Amgen Guides FY EPS $15.80-$17.08, Setting the Bar for 2026
AMGN sits 45% above its 52-week low of $269.77.
Summary
Amgen issued full-year EPS guidance of $15.80 to $17.08, a first look at management's 2026 expectations. The range comes amid a turbulent period: the FDA proposed withdrawing Tavneos, a key rare-disease drug, and the company disclosed a material cybersecurity breach just days ago. The guidance provides a concrete benchmark against which these headwinds can be measured. With the stock trading near its 52-week high, the market appears to be pricing in resilience, but the Tavneos withdrawal and data breach costs could pressure the lower end of the range. No consensus estimate was provided for comparison, so the initial market reaction will hinge on how this range stacks up against whisper numbers.
At the time of this announcement, AMGN was trading at $391.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $210.5B. The 52-week trading range was $269.77 to $398.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.